Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma
Chimeric antigen receptor T (CAR-T) cell therapy is an attractive strategy for patients with relapsed or refractory hematological malignancies including multiple myeloma (MM). T cells are engineered to attack malignant cells that express tumor-associated antigens and better efficacy could be achieve...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.898341/full |
| _version_ | 1811245682032377856 |
|---|---|
| author | Mengyi Du Linlin Huang Haiming Kou Chenggong Li Yu Hu Heng Mei |
| author_facet | Mengyi Du Linlin Huang Haiming Kou Chenggong Li Yu Hu Heng Mei |
| author_sort | Mengyi Du |
| collection | DOAJ |
| description | Chimeric antigen receptor T (CAR-T) cell therapy is an attractive strategy for patients with relapsed or refractory hematological malignancies including multiple myeloma (MM). T cells are engineered to attack malignant cells that express tumor-associated antigens and better efficacy could be achieved. However, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematologic toxicity are still challenges for CAR-T cell therapy. Among them, hematologic toxicity including thrombocytopenia has a longer duration and lasting effect during and after the treatment for some patients. Here, we present 3 cases of hematologic toxicity manifested as refractory thrombocytopenia with platelet autoantibodies positive and plasma thrombopoietin (TPO) concentration elevated after bispecific CAR-T cell therapy in relapsed/refractory (R/R) MM patients who were successfully treated with standard therapy of immune thrombocytopenia (ITP). Without clear pathogenesis or guidance on therapy published, our cases provide a reference for the treatment of thrombocytopenia after CAR-T cell therapy and inspire exploration of the underlying pathophysiological mechanisms. |
| first_indexed | 2024-04-12T14:42:06Z |
| format | Article |
| id | doaj.art-e9e1dd3df7544e5f92e8dc25baa62137 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T14:42:06Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-e9e1dd3df7544e5f92e8dc25baa621372022-12-22T03:28:47ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.898341898341Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple MyelomaMengyi DuLinlin HuangHaiming KouChenggong LiYu HuHeng MeiChimeric antigen receptor T (CAR-T) cell therapy is an attractive strategy for patients with relapsed or refractory hematological malignancies including multiple myeloma (MM). T cells are engineered to attack malignant cells that express tumor-associated antigens and better efficacy could be achieved. However, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematologic toxicity are still challenges for CAR-T cell therapy. Among them, hematologic toxicity including thrombocytopenia has a longer duration and lasting effect during and after the treatment for some patients. Here, we present 3 cases of hematologic toxicity manifested as refractory thrombocytopenia with platelet autoantibodies positive and plasma thrombopoietin (TPO) concentration elevated after bispecific CAR-T cell therapy in relapsed/refractory (R/R) MM patients who were successfully treated with standard therapy of immune thrombocytopenia (ITP). Without clear pathogenesis or guidance on therapy published, our cases provide a reference for the treatment of thrombocytopenia after CAR-T cell therapy and inspire exploration of the underlying pathophysiological mechanisms.https://www.frontiersin.org/articles/10.3389/fimmu.2022.898341/fullthrombocytopeniaITPCAR-T therapymultiple myelomaMAIPA |
| spellingShingle | Mengyi Du Linlin Huang Haiming Kou Chenggong Li Yu Hu Heng Mei Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma Frontiers in Immunology thrombocytopenia ITP CAR-T therapy multiple myeloma MAIPA |
| title | Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma |
| title_full | Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma |
| title_fullStr | Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma |
| title_full_unstemmed | Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma |
| title_short | Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma |
| title_sort | case report itp treatment after car t cell therapy in patients with multiple myeloma |
| topic | thrombocytopenia ITP CAR-T therapy multiple myeloma MAIPA |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.898341/full |
| work_keys_str_mv | AT mengyidu casereportitptreatmentaftercartcelltherapyinpatientswithmultiplemyeloma AT linlinhuang casereportitptreatmentaftercartcelltherapyinpatientswithmultiplemyeloma AT haimingkou casereportitptreatmentaftercartcelltherapyinpatientswithmultiplemyeloma AT chenggongli casereportitptreatmentaftercartcelltherapyinpatientswithmultiplemyeloma AT yuhu casereportitptreatmentaftercartcelltherapyinpatientswithmultiplemyeloma AT hengmei casereportitptreatmentaftercartcelltherapyinpatientswithmultiplemyeloma |